BHV-1300

DB22673InvestigationalProtein Based Therapies

BHV-1300 is a IgG1,2,4 selective degrader being investigated for the treatment of Grave's disease.

Mechanism: BHV-1300 selectively targets IgG1, IgG2, and IgG4. It is a bifunctional molecule that binds to IgG autoantibodies, then delivers the complex to asialoglycoprotein receptors on hepatocytes for internalization and lysosomal degradation.
Curator reviewed · 3 references
Code names: BHV-1300

Resolves to

Targets

What you can answer from here — as of June 30, 2026

4Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

9+ReferencesStructured and connected to the statements they support

Which drugs share a target with BHV-1300, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.